Pliant Therapeutics, Inc.
NASDAQ:PLRX
Overview | Financials
Company Name | Pliant Therapeutics, Inc. |
Symbol | PLRX |
Currency | USD |
Price | 12.63 |
Market Cap | 768,580,968 |
Dividend Yield | 0% |
52-week-range | 10.22 - 18.92 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Bernard Coulie M.B.A., M.D., MBA, Ph.D. |
Website | https://pliantrx.com |
An error occurred while fetching data.
About Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials.
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD